tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Invion Secures FDA Orphan Drug Designation for Anal Cancer

Story Highlights
Invion Secures FDA Orphan Drug Designation for Anal Cancer

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

The latest update is out from Invion ( (AU:IVX) ).

Invion Limited has confirmed that it received an Orphan Drug Designation from the U.S. FDA for anal cancer, which is expected to have a material effect on the company’s securities. The company became aware of the designation on 19 August 2025 and promptly took steps to verify the information and communicate with the ASX. Invion assures compliance with ASX Listing Rules and has authorized the disclosure of this information by its board.

More about Invion

Invion is a life-science company focused on the global research and development of Photosoft™ technology for treating various cancers, atherosclerosis, and infectious diseases. The company holds exclusive licensing and distribution rights in several regions, including Australia, New Zealand, and parts of Asia Pacific, for different medical indications. Invion’s research and clinical trials are funded by RMW Cho Group Limited, and it is listed on the ASX.

Average Trading Volume: 162,154

Technical Sentiment Signal: Sell

Current Market Cap: A$9.85M

Find detailed analytics on IVX stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1